文献速递妇科

子宫内膜癌中MLH1的表观遗传沉默与更大的肿瘤体积、更高的淋巴结阳性率及更短的无复发生存相关

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
PubMed 文献 · Gynecol Oncol · 2017-07-11

单中心队列对466例子宫内膜癌进行错配修复(MMR)分类,75%为MMR功能正常、20%为表观遗传MMR缺陷、5%为可能MMR突变。表观遗传MMR缺陷与晚期、高级别、淋巴血管间隙浸润、高龄及更大肿瘤体积相关,其晚期子宫内膜样癌复发率高于MMR功能正常组(47.7% vs 3.4%),早期复发无差异。

要点

  • 表观遗传MMR缺陷肿瘤中位体积10220mm3,高于MMR功能正常3321mm3和可能MMR突变2846mm3(P<0.0001)。
  • 晚期(III/IV期)子宫内膜样癌中,表观遗传MMR缺陷组复发率47.7%,MMR功能正常组3.4%。
  • 表观遗传MMR缺陷的子宫内膜样癌无复发生存显著缩短,早期病例复发数无差异。

核心结论

  • 包含MLH1甲基化分析的MMR检测可界定出一组预后特征更差且无复发生存缩短的肿瘤。

研究设计与样本

  • 单中心队列评估子宫内膜癌的MMR分类。
  • 共分类466例子宫内膜癌,采用MMR免疫组化±微卫星不稳定性(MSI)检测及反射性MLH1甲基化检测。
  • IHC或MSI提示MMR异常且MLH1甲基化者归为表观遗传MMR缺陷,无MLH1甲基化者归为可能MMR突变。

主要发现

  • 466例中75%为MMR功能正常,20%为表观遗传MMR缺陷,5%为可能MMR突变。
  • 表观遗传MMR缺陷与晚期、更高级别、淋巴血管间隙浸润及高龄相关。
  • 表观遗传MMR缺陷肿瘤中位体积10220mm3,MMR功能正常3321mm3,可能MMR突变2846mm3(P<0.0001)。
  • 更高肿瘤体积与淋巴结受累相关。
  • 晚期(III/IV期)子宫内膜样癌中,表观遗传MMR缺陷组复发率47.7%,MMR功能正常组3.4%,尽管接受相似辅助治疗。

关键数值与推荐

  • 表观遗传MMR缺陷肿瘤中位体积10220mm3 vs MMR功能正常3321mm3 vs 可能MMR突变2846mm3(P<0.0001)。
  • 晚期子宫内膜样癌表观遗传MMR缺陷组复发率47.7% vs MMR功能正常组3.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the relationship between mismatch repair (MMR) classification and clinicopathologic features including tumor volume, and explore outcomes by MMR class in a contemporary cohort. METHODS: Single institution cohort evaluating MMR classification for endometrial cancers (EC). MMR immunohistochemistry (IHC)±microsatellite instability (MSI) testing and reflex MLH1 methylation testing was performed. Tumors with MMR abnormalities by IHC or MSI and MLH1 methylation were classified as epigenetic MMR deficiency while those without MLH1 methylation were classified as probable MMR mutations. Clinicopathologic characteristics were analyzed. RESULTS: 466 endometrial cancers were classified; 75% as MMR proficient, 20% epigenetic MMR defects, and 5% as probable MMR mutations. Epigenetic MMR defects were associated with advanced stage, higher grade, presence of lymphovascular space invasion, and older age. MMR class was significantly associated with tumor volume, an association not previously reported. The epigenetic MMR defect tumors median volume was 10,220mm3 compared to 3321mm3 and 2,846mm3, for MMR proficient and probable MMR mutations respectively (P<0.0001). Higher tumor volume was associated with lymph node involvement. Endometrioid EC cases with epigenetic MMR defects had significantly reduced recurrence-free survival (RFS). Among advanced stage (III/IV) endometrioid EC the epigenetic MMR defect group was more likely to recur compared to the MMR proficient group (47.7% vs 3.4%) despite receiving similar adjuvant therapy. In contrast, there was no difference in the number of early stage recurrences for the different MMR classes. CONCLUSIONS: MMR testing that includes MLH1 methylation analysis defines a subset of tumors that have worse prognostic features and reduced RFS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cosgrove CM, Cohn DE, Hampel H, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017. PMID: 28709704. doi:10.1016/j.ygyno.2017.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。